Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Krebs Biochem
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 11.46 | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.10 | 5.48 | 4.17 | 7.27 | 6.81 |
| Expenses + | 16.08 | 13.20 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 | 6.97 | 7.67 |
| Operating Profit | -4.62 | -2.62 | -0.90 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 | -2.80 | 0.30 | -0.86 |
| OPM % | -40.31% | -24.76% | -6.04% | -16.10% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% | -67.15% | 4.13% | -12.63% |
| Other Income + | 0.19 | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 | 0.00 | 2.00 |
| Interest | 1.03 | 1.10 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 | 1.79 | 1.91 |
| Depreciation | 1.48 | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.60 | 1.62 | 1.63 | 1.57 |
| Profit before tax | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 | -6.14 | -3.12 | -2.34 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit + | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 | -6.14 | -3.13 | -2.34 |
| EPS in Rs | -3.22 | -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 | -1.45 | -1.09 |
Financials of Krebs Biochem
Annual income statement trend
| Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 24 |
| Expenses + | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 29 |
| Operating Profit | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -5 |
| OPM % | -1,088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -23% | |
| Other Income + | 3 | 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 |
| Interest | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 6 |
| Profit before tax | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit + | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 |
| EPS in Rs | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.50 | -7.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Krebs Biochem
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 9 | -0 | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 | -184 |
| Borrowings + | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 225 |
| Other Liabilities + | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 101 |
| Total Liabilities | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
| Fixed Assets + | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 142 |
| CWIP | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total Assets | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
Financials of Krebs Biochem
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -45 | -15 | -11 | -6 | 4 | -36 | -15 | -17 | -25 | 2 | -8 | -2 |
| Cash from Investing Activity + | -3 | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 | -5 | -4 |
| Cash from Financing Activity + | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 | 6 |
| Net Cash Flow | 6 | -6 | -0 | 0 | 17 | -17 | 1 | -1 | -0 | 0 | 0 | -0 |
| Free Cash Flow | -48 | -23 | -17 | -9 | -1 | -45 | -40 | -41 | -36 | -5 | -11 | -5 |
| CFO/OP | 924% | 123% | 140% | 83% | -40% | 191% | 83% | 51% | 157% | -27% | 52% | 35% |
Financials of Krebs Biochem
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | 0 | |
| Inventory Days | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | ||
| Days Payable | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | ||
| Cash Conversion Cycle | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | 0 | |
| Working Capital Days | -6,532 | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | -1,593 | |
| ROCE % | -8% | -26% | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% | -15% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…